The number of clinical trials taking place in Russia in 2013 amounted 791, which is 13.6% lower than the year earlier, according to data of the Russian Ministry of Health.
The decline was observed in the clinical studies conducted both by domestic and foreign companies operating in the country.
In case of Russian companies, the number of clinical studies declined by 25% to 279. At the same time the number of international multicenter studies declined by 9.5% to 334. The growth was only observed in the segment of local researches that is carried out by foreign companies, which rose from 169 in 2012 to 178 in 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze